Innovent Biologics (HKSE:01801) 3-Year Revenue Growth Rate : 9.00% (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics 3-Year Revenue Growth Rate?

Innovent Biologics's Revenue per Share for the six months ended in Jun. 2024 was HK$2.62.

During the past 12 months, Innovent Biologics's average Revenue per Share Growth Rate was 38.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 9.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 124.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 8 years, the highest 3-Year average Revenue per Share Growth Rate of Innovent Biologics was 451.70% per year. The lowest was 9.00% per year. And the median was 216.75% per year.

Competitive Comparison of Innovent Biologics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Innovent Biologics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's 3-Year Revenue Growth Rate falls into.

Innovent Biologics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Innovent Biologics (HKSE:01801) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Innovent Biologics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
Yu De-chao Michael	2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Eight Roads Investments	2101 Beneficial owner
Fullerton Management Pte Ltd	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited	2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd.	2101 Beneficial owner

Innovent Biologics Headlines

No Headlines